A combination vaccine targeting COVID-19 and influenza demonstrates promising results


The development of a combination vaccine targeting both COVID-19 and influenza marks a significant milestone in the ongoing battle against respiratory illnesses. Moderna, a leading pharmaceutical company, recently announced promising results from phase 3 clinical trials of its experimental vaccine, mRNA-1083. This innovative vaccine combines Moderna’s mRNA-1010, designed to combat seasonal influenza, with mRNA-1283, the company’s next-generation COVID-19 vaccine candidate.

According to Moderna’s press release, mRNA-1083 demonstrated a superior immune response compared to other vaccines in phase 3 trials. Francesca Ceddia, Moderna’s chief medical affairs officer, emphasized the potential impact of this combination vaccine on public health. She highlighted the convenience of dual protection in a single shot and the potential for enhanced immunity against two respiratory diseases that impose a significant burden on healthcare systems worldwide.

The prospect of a flu and COVID-19 combination vaccine has generated considerable interest within the medical community and beyond. With COVID and flu vaccine rates declining among US healthcare workers, there is a pressing need for innovative solutions to boost immunization coverage and prevent outbreaks. Moderna’s breakthrough represents a step forward in addressing this challenge, offering hope for improved compliance and better outcomes in the fight against respiratory illnesses.

Moderna’s phase 3 trial involved two independent groups of 4,000 adults each, providing valuable insights into the vaccine’s efficacy and safety profile. One group comprised adults aged 65 and older, while the other included adults aged 50 to 64 years old. In both groups, mRNA-1083 elicited statistically significantly higher immune responses against three influenza virus strains (H1N1, H3N2, and B/Victoria) and SARS-CoV-2 compared to other vaccines.

Amrie Grammer, a Virginia-based immunologist, underscored the importance of Moderna’s findings in the context of COVID and flu-related mortality rates, particularly among older adults. Grammer noted that 90% of COVID-related deaths and 70% to 85% of flu-related deaths in 2023 occurred in individuals aged 65 and older. By simplifying the vaccination process and offering dual protection against these serious infections, mRNA-1083 has the potential to save lives and reduce the burden on healthcare systems.

Despite the promising results, experts caution that rare adverse events cannot be entirely predicted. As with any vaccine, ongoing surveillance and monitoring are essential to identify and address potential safety concerns. However, Moderna’s positive phase 3 trial outcomes represent a significant advancement in the development of combination vaccines targeting respiratory illnesses.

Looking ahead, the potential approval and widespread adoption of a flu and COVID-19 combination vaccine could have far-reaching implications for public health. By streamlining vaccination efforts and enhancing immunity against multiple pathogens, this innovative approach has the potential to revolutionize disease prevention strategies and mitigate the impact of future outbreaks.

In conclusion, Moderna’s progress in developing a combination COVID-influenza vaccine offers a glimmer of hope in the fight against respiratory illnesses. With promising phase 3 trial results and the potential for enhanced protection and convenience, mRNA-1083 represents a significant step forward in the quest to safeguard public health. As efforts continue to combat COVID-19 and influenza, innovative solutions like combination vaccines hold immense promise for a healthier and more resilient future.


Please enter your comment!
Please enter your name here

Enable Google Transliteration.(To type in English, press Ctrl+g)